A U.S. study on 74 HIV-positive patients found that those who received gene therapy had lower viral counts and higher amounts of CD4 cells after 100 weeks than those who received placebo. Researchers also did not find any adverse events linked to the gene treatment. The therapy uses blood stem cells equipped with a disabled virus containing a gene that encodes an RNA enzyme, which inhibits the replication of the virus after a cell becomes infected.

Full Story:

Related Summaries